Vaxart, Inc. - Common Stock

0.57 USD
+0.00 (+0.40%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Vaxart, Inc. - Common Stock stock is down -40.14% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35.42% of the previous 50 June’s closed higher than May.

About Vaxart, Inc. - Common Stock

Vaxart, Inc. engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.